Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Search Results to Gregory G Schwartz

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Schwartz, Gregory

Item TypeName
Academic Article Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Academic Article Lipid lowering in acute coronary syndromes: new evidence, new questions.
Academic Article Early initiation of treatment with statins in acute coronary syndromes.
Academic Article Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
Academic Article Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Academic Article High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Academic Article The case for intensive statin therapy after acute coronary syndromes.
Academic Article Intensive statin therapy reduces clinical events at 30 days and after six months in acute coronary syndromes.
Academic Article Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Academic Article Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
Academic Article Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Academic Article High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome.
Academic Article Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients.
Academic Article Exploring new strategies for the management of acute coronary syndromes.
Academic Article Statins for acute coronary syndrome.
Academic Article Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Academic Article Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Academic Article Dalcetrapib in patients with an acute coronary syndrome.
Academic Article High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Academic Article Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.
Academic Article Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.
Academic Article Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).
Academic Article High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Academic Article Statins in acute coronary syndromes: the sooner, the better?
Academic Article Lipid management after acute coronary syndrome.
Academic Article Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
Academic Article Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Academic Article Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study.
Concept Acute Coronary Syndrome
Academic Article Evaluation of the dual peroxisome proliferator-activated receptor a/? agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Academic Article Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Academic Article Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Academic Article Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Academic Article Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
Academic Article Statins for acute coronary syndrome.
Academic Article Cochrane corner: early statin therapy in acute coronary syndromes--what is the clinical benefit?
Academic Article Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.
Academic Article Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
Academic Article Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute?Coronary Syndrome.
Academic Article Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome.
Academic Article Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.
Academic Article Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.
Academic Article Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
Academic Article Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Academic Article Effect of Serial Infusions of CER-001, a Pre-? High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
Academic Article Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Academic Article Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Academic Article Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Academic Article Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary?Syndrome: ODYSSEY OUTCOMES Trial.
Academic Article Alirocumab after Acute Coronary Syndrome. Reply.
Academic Article Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Academic Article Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Academic Article Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
Academic Article Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Academic Article Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Academic Article Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.
Academic Article Initiating PCSK9 Inhibition in Hospital for ACS: We Can, But Does That Mean We Should?
Academic Article Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Academic Article Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
Academic Article Reply: Alirocumab in Polyvascular Atherosclerotic Disease.
Academic Article Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute?Coronary Syndrome.
Academic Article Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY?OUTCOMES.
Academic Article Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.
Academic Article Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
Academic Article Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Academic Article Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Academic Article Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial".
Academic Article Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Academic Article Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Academic Article Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
Academic Article Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.
Academic Article Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Academic Article Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Academic Article Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Academic Article Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Academic Article Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial.
Academic Article Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Academic Article Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
Academic Article Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES.
Academic Article Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Academic Article Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
Academic Article Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Academic Article Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes.
Academic Article Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Academic Article Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Academic Article Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.
Academic Article Correction: Effect of?alirocumab on?cataracts in?patients with?acute coronary syndromes.
Academic Article Effect of alirocumab on cataracts in patients with acute coronary syndromes.
Academic Article Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Academic Article Impact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndrome.

Search Criteria
  • Acute Coronary Syndrome

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)